Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Ellassais-Schaap, Muralidhar Beerram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone, and Anthony W. Tolcher

Abstract

Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with advanced solid tumors.

Experimental Design: In a 3 + 3 dose escalation study, 10 patients received pembrolizumab 1, 3, or 10 mg/kg intravenously every 2 weeks until progression or intolerable toxicity. Seven additional patients received 10 mg/kg every 2 weeks.

Results: No dose-limiting toxicities were observed. Maximum administered dose was 10 mg/kg every 2 weeks. One patient with melanoma and one with Merkel cell carcinoma experienced complete responses of 57 and 56+ weeks’ duration, respectively. Three patients with melanoma experienced partial responses. Fifteen patients with various malignancies experienced stable disease. One patient died of cryptococcal infection 92 days after pembrolizumab discontinuation, following prolonged corticosteroid use for grade 2 gastritis considered drug related. Pembrolizumab exhibited pharmacokinetic characteristics typical of humanized monoclonal antibodies. Maximum serum target engagement was reached with trough levels of doses greater than or equal to 1 mg/kg every 3 weeks. Mechanism-based translational models with a focus on intratumor exposure prediction suggested robust clinical activity would be observed at doses ≥2 mg/kg every 3 weeks.

Conclusions: Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors. The lowest dose with full potential for antitumor activity was 2 mg/kg every 3 weeks.

See related commentary by van Elsas et al., p. 4251

Introduction

Immune checkpoint inhibitors have demonstrated utility as targets in advanced cancer, with evidence of overall survival benefit and durable response (1–2). Programmed death receptor 1 (PD-1) is an inhibitory receptor expressed on the surface of activated T cells (3, 4) normally involved with immune tolerance and preventing tissue damage associated with chronic inflammation (5). Interaction of PD-1 with its ligands, programmed death ligands 1 and 2 (PD-L1 and PD-L2), dampens T-cell receptor signaling, leading to downregulation of T-cell activation, proliferation, and T-cell–mediated antitumor immune response (6–8). The PD-1 pathway represents one of the immune checkpoints used by tumors to suppress antitumor immunity (5). Studies using mouse models of various tumor types demonstrated enhanced T-cell function and antitumor responses with anti–PD-1 and anti–PD-L1 antibodies (5, 9–11).

PD-1 and PD-L1 inhibition have also shown acceptable safety and tolerability and promising antitumor activity in patients with advanced solid tumors (12–20).

Pembrolizumab (MK-3475) is a potent, highly selective, IgG4-x humanized monoclonal antibody that prevents PD-1 binding with PD-L1 and PD-L2. This agent was generated by grafting the variable region sequences of a mouse antihuman PD-1 antibody onto a human IgG4-x isotype framework containing a stabilizing S228P Fc mutation (Fig. 1). Pembrolizumab shows high affinity for the PD-1 receptor, strong inhibition of PD-L1 and PD-L2, and robust activity in a functional ex vivo T-cell modulation assay using human donor blood cells (data on file; Merck & Co., Inc.).

The objectives of this first-in-human phase I study were to evaluate the safety, pharmacokinetics, and pharmacodynamics of pembrolizumab in patients with advanced solid tumors. Pharmacodynamics were characterized using an assay based on immune activation. Additional objectives were to explore the...
antitumor activity and identify the maximum tolerated dose (MTD) of pembrolizumab.

**Materials and Methods**

**Patient population**

Patients were eligible for enrollment if they were 18 years or older, had a histologically or cytologically confirmed advanced solid tumor, experienced disease progression on or were intolerant of or not eligible for standard therapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had adequate organ function. Key exclusion criteria included previous treatment with a PD-1, PD-L1, or cytotoxic T-lymphocyte–associated protein 4 inhibitor, requirement for chronic systemic steroid therapy, and presence of active autoimmune disease or infections. Patients with previously treated brain metastases were eligible if they were clinically stable for at least 8 weeks before enrollment (the first 7 patients enrolled were eligible if they were clinically stable for at least 4 weeks). All patients provided written informed consent.

**Study design**

KEYNOTE-001 is a large, international, multicohort, phase I study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (ClinicalTrials.gov identifier NCT01295827). The study protocol and all amendments were approved by the appropriate institutional review boards or ethics committees. This manuscript reports on the initial open-label, dose-escalation, expansion cohorts that were conducted at 2 sites in the United States. Dose escalation (Part A) was conducted using a traditional 3+3 design, with cohorts of 3 patients sequentially enrolled at pembrolizumab doses of 1, 3, and 10 mg/kg [predetermined maximum administered dose (MAD)] administered intravenously over 30 minutes on days 1 and 28 and every 14 days thereafter until disease progression or intolerable toxicity occurred. Dosing decisions were based on the rate of dose-limiting toxicities (DLTs) observed during the first 28-day treatment cycle. The prespecified DLTs were grade 4 nonhematologic toxicity, grade 3 nonhematologic toxicity lasting >3 days despite optimal supportive care, grade 3 nonhematologic laboratory value that persisted for >1 week or required medical intervention or hospitalization, grade ≥3 febrile neutropenia, and grade 4 thrombocytopenia requiring platelet transfusion or leading to a life-threatening bleeding event. Part A-1 included 7 additional patients enrolled at the MAD. In Part A-2, which was conducted to more fully define the relationship between pharmacokinetics and pharmacodynamics, 13 patients were randomly assigned to one of three parallel, 3-week, intrapatient dose-escalation schedules (dose range, 0.005–10 mg/kg), followed by treatment with 2 or 10 mg/kg every 3 weeks (Supplementary Table S1). The design was powered to quantify dose-linearity and pharmacodynamics potency in a wide range. Doses lower than 1.0 mg/kg were administered as an intravenous bolus; doses of 1.0 mg/kg or larger were administered via 30-minute intravenous infusion.

**Assessments**

Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Investigators indicated whether an AE was potentially immune related (irAE). irAEs were defined as AEs of unknown etiology associated with pembrolizumab exposure that were consistent with an immune phenomenon. Tumor response was assessed every 2 months for the first 12 months and every 3 months thereafter by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1).

For pharmacokinetic analyses in the dose-escalation and expansion cohorts, venous blood samples were collected predose, postdose (<30 minutes after infusion), and 6 (±2), 24 (±2), and 48 (±2) hours after the start of the first infusion; on days 8, 15, 22, and 29 of cycle 1; predose and postdose in cycle 2 and every other cycle thereafter for the first 12 months; and 30 days after the last pembrolizumab dose. A similar sampling scheme was deployed for Part A-2 (Supplementary Table S1). Pembrolizumab serum concentrations were quantified using a validated electrochemiluminescent assay [lower limit of quantification (LLOQ), ≥10 ng/mL]. Pharmacokinetic data were described using non-compartmental approaches, and, together with PD-1 receptor modulation data, a pharmacokinetic–pharmacodynamic population model was developed.

PD-1 receptor modulation was assessed in venous blood samples collected predose and at various time points after infusion (see Supplementary Materials, for complete methodology).

---

**Translational Relevance**

The programmed death receptor 1 (PD-1) pathway is an immune checkpoint inhibitor exploited by tumor cells to suppress antitumor immunity. Pembrolizumab (MK-3475) is a potent, highly selective, IgG4-k humanized monoclonal antibody that prevents PD-1 binding with its ligands, PD-L1 and PD-L2. This report details the first-in-human experience for pembrolizumab in patients with advanced solid tumors, including in-depth pharmacokinetic and pharmacodynamic analyses. No dose-limiting toxicities occurred, and promising antitumor activity, including complete responses, were observed. Translational modeling suggested that the minimal dose at which clinical activity would be observed is 2 mg/kg given once every 3 weeks. The results of this study support the continued development of pembrolizumab for various tumor types, as well as the recent approval of pembrolizumab doses of 1, 3, and 10 mg/kg [predetermined maximum administered dose (MAD)] administered intravenously over 30 minutes on days 1 and 28 and every 14 days thereafter until disease progression or intolerable toxicity occurred. Dosing decisions were based on the rate of dose-limiting toxicities (DLTs) observed during the first 28-day treatment cycle. The prespecified DLTs were grade 4 nonhematologic toxicity, grade 3 nonhematologic toxicity lasting >3 days despite optimal supportive care, grade 3 nonhematologic laboratory value that persisted for >1 week or required medical intervention or hospitalization, grade ≥3 febrile neutropenia, and grade 4 thrombocytopenia requiring platelet transfusion or leading to a life-threatening bleeding event. Part A-1 included 7 additional patients enrolled at the MAD. In Part A-2, which was conducted to more fully define the relationship between pharmacokinetics and pharmacodynamics, 13 patients were randomly assigned to one of three parallel, 3-week, intrapatient dose-escalation schedules (dose range, 0.005–10 mg/kg), followed by treatment with 2 or 10 mg/kg every 3 weeks (Supplementary Table S1). The design was powered to quantify dose-linearity and pharmacodynamics potency in a wide range. Doses lower than 1.0 mg/kg were administered as an intravenous bolus; doses of 1.0 mg/kg or larger were administered via 30-minute intravenous infusion.

**Assessments**

Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Investigators indicated whether an AE was potentially immune related (irAE). irAEs were defined as AEs of unknown etiology associated with pembrolizumab exposure that were consistent with an immune phenomenon. Tumor response was assessed every 2 months for the first 12 months and every 3 months thereafter by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1).

For pharmacokinetic analyses in the dose-escalation and expansion cohorts, venous blood samples were collected predose, postdose (<30 minutes after infusion), and 6 (±2), 24 (±2), and 48 (±2) hours after the start of the first infusion; on days 8, 15, 22, and 29 of cycle 1; predose and postdose in cycle 2 and every other cycle thereafter for the first 12 months; and 30 days after the last pembrolizumab dose. A similar sampling scheme was deployed for Part A-2 (Supplementary Table S1). Pembrolizumab serum concentrations were quantified using a validated electrochemiluminescent assay [lower limit of quantification (LLOQ), ≥10 ng/mL]. Pharmacokinetic data were described using non-compartmental approaches, and, together with PD-1 receptor modulation data, a pharmacokinetic–pharmacodynamic population model was developed.

PD-1 receptor modulation was assessed in venous blood samples collected predose and at various time points after infusion (see Supplementary Materials, for complete methodology).
Briefly, 1:10 dilutions of whole blood were incubated with staphylococcal enterotoxin B (SEB) alone or with SEB plus pembrolizumab 25 μg/ml for 4 days at 37°C. Interleukin (IL) 2 concentrations were measured in the supernatant using the Human IL2 Ultra-Sensitive Kit (Meso Scale Diagnostics, LLOQ, 4.0 pg/ml). The stimulation ratio was calculated by dividing the IL2 concentration measured in a sample treated with SEB plus pembrolizumab by the IL2 concentration measured in the same sample treated with SEB alone. This process effectively compares the stimulation achieved by endogenous levels of pembrolizumab to the maximal stimulation possible. At maximal pembrolizumab concentrations, the IL2 level in both samples was approximately equal, leading to a stimulation ratio of approximately 1.

If available, archived tumor tissue was collected from consenting patients. Although not mandatory, newly collected biopsy specimens of readily accessible tumor lesions were obtained within 60 days of the first pembrolizumab dose and 2 months after the start of therapy. PD-L1 expression was measured by immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue sections using an assay developed by Merck Research Laboratories (see Supplementary Materials, for complete methodology). Samples scored as positive had membranous PD-L1 labeling of >5% of cells along the margins of tumor nodules that extended into the tumor parenchyma and clearly involved labeling of tumor cells. PD-L1 signal in samples scored as negative ranged from absent to sparse, was random in distribution, and was consistently absent from tumor cells.

Viral antigen recall

The interferon gamma (IFNγ) enzyme-linked immunospot (ELISPOT) assay was performed to assess the effect of pembrolizumab treatment on overall T-cell response to viral infection (see Supplementary Materials, for complete methodology). Briefly, peripheral blood mononuclear cell samples were collected at pretreatment; days 3, 8, 15, and 22; and cycle 2, day 1 preinfusion time points and stimulated with a pool of peptides of Epstein-Barr virus, cytomegalovirus, and influenza virus restricted to MHC class I molecules (CEF-32). Samples were analyzed using the IFNγ ELISPOT assay (21).

Results

Patients

Between April 27, 2011, and August 1, 2012, 32 patients were enrolled. Two patients did not receive treatment (1 because of rapid tumor progression and 1 because of ongoing infection) and were excluded from all analyses. Part A included 4 patients enrolled at pembrolizumab 1 mg/kg (because of rapid clinical progression, pharmacokinetics were not assessable for 1 patient, who was replaced) and 3 patients each enrolled at 3 and 10 mg/kg, all dosed every 2 weeks. Part A-1 enrolled 7 patients, all treated at a maximum dose of 2 mg/kg every 3 weeks, and 6 patients were treated at a maximum dose of 10 mg/kg every 3 weeks. As of the October 18, 2013, analysis cutoff date, 28 of 30 patients had discontinued pembrolizumab (n = 13 for disease progression, n = 12 for AE of any attribution, and n = 3 for physician decision).

Patients had a variety of tumor types, including melanoma (n = 7) and non–small cell lung cancer (NSCLC, n = 6; Table 1). Median age was 66.5 years (range, 33–87 years), 77% of patients were men, and 67% had an ECOG performance status of 1. Most patients (83%) received at least one previous therapy, and 50% received three or more previous therapies.

Safety

During dose escalation, no DLTs were observed, and no MTD was defined. Per protocol, the MAD was 10 mg/kg every 2 weeks. Treatment-related AEs occurring in 21 patients (70%) (Table 2). There were no grade 3 or 4 treatment-related AEs. Treatment-related AEs occurring in more than 1 patient were fatigue (n = 10; 33%), nausea (n = 7; 23%), pruritus (n = 5; 17%), decreased appetite (n = 4; 13%), and diarrhea and hypothyroidism (n = 2 each; 7%). Three patients (10%) discontinued therapy because of treatment-related AEs [n = 1 each for grade 2 fatigue (date of onset, day 235), pneumonitis (date of onset, day 242), and decreased weight (date of onset, day 168)]. A 76-year-old man with advanced melanoma, whose best overall response to pembrolizumab 10 mg/kg every 2 weeks was partial response, discontinued treatment because of decreased weight. He experienced recurrent grade 2 gastritis and was treated with oral prednisone 80 mg/day. After a prolonged course of prednisone, the patient developed disseminated multiorgan cryptococcal infection and died 92 days after discontinuing pembrolizumab. Autopsy confirmed cryptococcal infection as the cause of death, which the investigator considered possibly related to treatment.

As designated by the investigators, irAEs occurred in 5 patients (17%): grade 1 fatigue, erythema, and hypothyroidism and grade 2 gastritis and pneumonitis. The case of grade 2 pneumonitis occurred in an 81-year-old woman with leiomysarcoma. After 15 doses of pembrolizumab 3 mg/kg every 2 weeks, she presented with dyspnea and cough. Grade 2 pneumonitis was diagnosed after computed tomography and bronchoscopy, and pembrolizumab was permanently discontinued. She was treated with prednisone 10 mg/day on a 14-day tapering regimen and empirically

<table>
<thead>
<tr>
<th>Table 1. Baseline characteristics of treated patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Parts A and A-1, n = 17</th>
<th>Part A-2, n = 13</th>
<th>All patients, N = 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, median (range)</td>
<td>67.0 (35–87)</td>
<td>66.0 (33–82)</td>
<td>66.5 (33–87)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>10 (59)</td>
<td>13 (100)</td>
<td>23 (77)</td>
</tr>
<tr>
<td>Female</td>
<td>7 (41)</td>
<td>0 (0)</td>
<td>7 (23)</td>
</tr>
<tr>
<td>ECOG performance status, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>5 (29)</td>
<td>5 (38)</td>
<td>10 (33)</td>
</tr>
<tr>
<td>1</td>
<td>12 (71)</td>
<td>8 (62)</td>
<td>20 (67)</td>
</tr>
<tr>
<td>Tumor type, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>2 (12)</td>
<td>0 (0)</td>
<td>2 (7)</td>
</tr>
<tr>
<td>Carcinoid/neuroendocrine</td>
<td>2 (12)</td>
<td>1 (8)</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Colorectal</td>
<td>3 (18)</td>
<td>0 (0)</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>2 (12)</td>
<td>5 (38)</td>
<td>7 (23)</td>
</tr>
<tr>
<td>Merkel cell carcinoma</td>
<td>0 (0)</td>
<td>1 (8)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Non–small cell lung cancer</td>
<td>5 (29)</td>
<td>1 (8)</td>
<td>6 (20)</td>
</tr>
<tr>
<td>Prostate</td>
<td>1 (6)</td>
<td>2 (15)</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>1 (6)</td>
<td>0 (0)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Soft tissue sarcoma</td>
<td>1 (6)</td>
<td>0 (0)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Peripheral nerve sheath tumor</td>
<td>0 (0)</td>
<td>1 (8)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Pancreatic adenocarcinoma</td>
<td>0 (0)</td>
<td>1 (8)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Squamous cell lung cancer</td>
<td>0 (0)</td>
<td>1 (8)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Prior therapies, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0 (0)</td>
<td>5 (38)</td>
<td>5 (17)</td>
</tr>
<tr>
<td>1</td>
<td>2 (12)</td>
<td>3 (23)</td>
<td>5 (17)</td>
</tr>
<tr>
<td>2</td>
<td>2 (12)</td>
<td>3 (23)</td>
<td>5 (17)</td>
</tr>
<tr>
<td>&gt;3</td>
<td>13 (76)</td>
<td>2 (15)</td>
<td>15 (50)</td>
</tr>
</tbody>
</table>

Abbreviation: ECOG, Eastern Cooperative Oncology Group.
levofloxacin 350 mg/day for 10 days. Pneumonitis improved to grade 1 after completion of corticosteroids and levofloxacin.

**Antitumor activity**

Antitumor activity was observed at all doses and schedules. Per investigator review as assessed by RECIST v1.1, 2 patients experienced complete response (Fig. 2; Supplementary Table S2). One complete response was observed in a patient with previously untreated Merkel cell carcinoma who received pembrolizumab 2 mg/kg every 3 weeks. At the time of the analysis cutoff date, response was ongoing with a duration of 56 weeks (Supplementary Table S2). Examination of the database beyond the cutoff date shows that this patient remains on treatment (duration, 100 weeks). As of the last on-study imaging performed on
June 11, 2014, the duration of response was 90 weeks and was ongoing (Supplementary Table S2). As of February 2015, the patient remains free of disease. The second complete response was observed in a patient with melanoma treated with pembrolizumab 10 mg/kg every 3 weeks (Fig. 3A). As of the last on-treatment scan performed on April 20, 2017.© 2015 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from

Pharmacokinetics and pharmacodynamics

Noncompartmental analysis of Parts A and A-1 suggested a half-life of 14 to 22 days and potential nonlinearity between 1 and 3 mg/kg, but the limited number of patients and a short observation window warrant careful interpretation (Table 3). Ex vivo IL2 stimulation to assess PD-1 receptor modulation suggested complete peripheral target engagement starting at 1 mg/kg that was durable for at least 21 days, with no differentiation among 1, 3, and 10 mg/kg (Fig. 4A). Preliminary pharmacokinetic and pharmacodynamic modeling assessment of these data indicated an initial IC50 of 1.3 μg/mL, which was associated with high uncertainty because of the limited data at this concentration. To provide a robust assessment of dose linearity and target engagement potency, Part A-2 was designed to include doses substantially lower than those expected to demonstrate pharmacodynamics activity.

Table 3. Summary statistics for PK parameters, Parts A and A-1

<table>
<thead>
<tr>
<th>Dose</th>
<th>n</th>
<th>Cmax, μg/mL, geometric mean (CV%)</th>
<th>Tmax, days, median (range)</th>
<th>AUC0–28, μg day/mL, geometric mean (CV%)</th>
<th>AUC0–∞, μg day/mL, geometric mean (CV%)</th>
<th>t1/2, days, geometric mean (CV%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg/kg</td>
<td>4</td>
<td>16.4 (22)</td>
<td>0.05 (0.02–0.17)</td>
<td>158 (20)</td>
<td>212 (36)</td>
<td>14.1 (50)</td>
</tr>
<tr>
<td>3 mg/kg</td>
<td>3</td>
<td>107 (26)</td>
<td>0.17 (0.17–0.17)</td>
<td>955 (23)</td>
<td>1530 (28)</td>
<td>21.6 (10)</td>
</tr>
<tr>
<td>10 mg/kg</td>
<td>10</td>
<td>256 (37)</td>
<td>0.17 (0.03–0.99)</td>
<td>2350 (31)</td>
<td>3270 (44)</td>
<td>17.7 (56)</td>
</tr>
</tbody>
</table>

Abbreviations: AUC0–28, area under the concentration–time curve from day 0 up to day 28; AUC0–∞, area under the concentration–time curve from day 0 to infinity; Cmax, maximum observed serum concentration; CV, coefficient of variation; PK, pharmacokinetic; t1/2, elimination half-life; Tmax, time of maximum observed serum concentration.

*n = 3 (1 patient excluded because of treatment discontinuation).

*n = 3 from Part A and N = 7 from Part A-1.

*n = 9 (1 patient excluded because of treatment discontinuation).
The weekly intrapatient dose escalation in Part A-2, starting from a dose of 0.005 mg/kg and escalating to 10 mg/kg in 3 weeks, allowed precise assessment of dose linearity and potency (Fig. 4B). Serum exposure to pembrolizumab appeared linear in the range of 0.1 to 10 mg/kg at steady state dosing, whereas a nonlinear clearance component was associated with lower doses or with concentrations lower than 0.68 mg/mL (Fig. 4C). Pharmacodynamic response was best described by an \( I_{\text{max}} \) inhibition model with an \( IC_{50} \) of 0.535 mg/mL and maximal inhibition close to 1, where a ratio of 1 reflects stimulation close to the maximal stimulation under the saturating reference (i.e., maximal inhibitory activity or pembrolizumab; Fig. 4D). Subsequent simulations demonstrated how target engagement increased as a function of concentration and dose, with full saturation at doses of 1 mg/kg every 3 weeks or higher. Further evaluation of pharmacodynamics conducted by translational modeling, with a focus on intratumor exposure predictions bridging from mouse to human (manuscript in preparation), predicted robust responses at doses of 2 mg/kg every 3 weeks and higher and no or limited activity at doses lower than 1.0 mg/kg every 3 weeks.

**Viral antigen recall**

The IFN\( \gamma \) ELISPOT assay was performed on blood samples from 17 patients. Results of testing using the Wilcoxon signed rank test indicated no significant change in IFN\( \gamma \) production after pembrolizumab treatment, indicating no compromise of overall T-cell–mediated immune response (Supplementary Fig. S1).

**PD-L1 expression**

There were 15 patients for whom tumor biopsy samples were available for PD-L1 assessment. Of these, tumor PD-L1 expression was evaluable in 14 patients. Two patients, both of whom had...
melanoma and experienced PR, had PD-L1–positive tumors, defined as PD-L1 expression in >5% of cells. Among the 12 patients with PD-L1–negative tumors, best response was stable disease for 6 patients [hormone receptor-positive breast adenocarcinoma, carcinoid, NSCLC adenocarcinoma, pancreatic neuroendocrine carcinoma, prostate cancer, and melanoma (n = 1 each)] and progressive disease for 6 patients [colon adenocarcinoma (n = 1), squamous NSCLC (n = 1), rectal adenocarcinoma (n = 2), and NSCLC adenocarcinoma (n = 2)]. Samples from the 2 patients who experienced complete response were not evaluated for PD-L1 expression.

Discussion

This first-in-human experience showed that pembrolizumab can be administered safely at doses of 1 mg/kg every 2 weeks to 10 mg/kg every 2 weeks. Most treatment-related AEs associated with pembrolizumab were low grade and manageable with the use of symptom management and treatment interruption. Only 3 patients (10%) discontinued pembrolizumab because of treatment-related AEs. One patient died of cryptococcal infection following a prolonged course of prednisone for treatment-related grade 2 gastritis, underscoring the importance of aggressive monitoring for opportunistic infections while patients are treated with immunosuppressive therapy for immune-related AEs. One patient who received oral corticosteroids for treatment-related AEs (grade 2 fatigue and decreased appetite) experienced continued confirmed response of at least 5 months’ duration following corticosteroid use. The impact of corticosteroid use on outcomes in patients treated with pembrolizumab should be assessed in a larger patient population.

Although not powered for efficacy, pembrolizumab demonstrated evidence of antitumor activity in multiple tumor types, including melanoma, NSCLC, and Merkel cell carcinoma. Patients with melanoma appeared to derive particular benefit, with 6 of 7 patients experiencing stable disease or better, including 3 confirmed partial responses and 1 complete response. Complete response was also observed in a patient with Merkel cell carcinoma. Disease stabilization was observed in patients with various tumor types, including 4 of 7 patients with NSCLC. Durable disease stabilization of 27 weeks’ duration was observed in a patient with leiomyosarcoma. Taken together, the data from this study, though preliminary, provide an indication of the potentially broader application of pembrolizumab.

Among patients with data for tumor PD-L1 expression as assessed by immunohistochemistry, only 2 patients, both with melanoma, had PD-L1–positive tumors. These were the only patients with evaluable PD-L1 expression who experienced partial response. Six of the 12 patients with PD-L1–negative tumors had a best overall response of stable disease. The relationship between PD-L1 staining and antitumor activity cannot be adequately ascertained in this exploratory analysis because provision of archival tumor samples was not required for enrollment and tissue samples were available for only 15 patients. The role of PD-L1 staining in patients with multiple tumor types treated with pembrolizumab is being explored in ongoing trials.

Pharmacokinetic and pharmacodynamic data support dosing of pembrolizumab every 2 or 3 weeks at doses of 1 mg/kg or higher. Confirmed responses were observed at all doses except 1 mg/kg every 2 weeks, and all doses were well tolerated. These results, together with pharmacokinetic-pharmacodynamic and translational modeling, suggested a pembrolizumab dose range of 2 mg/kg every 3 weeks to 10 mg/kg every 2 weeks is safe and effective and provided the rationale for studying a range of doses in subsequent clinical trials. The optimal pembrolizumab dose regimen is under investigation in multiple randomized studies being conducted in patients with various advanced solid tumors.

At this time, the optimal treatment duration is unknown. In the present patient population, it is interesting to note that responses and disease stabilization continued after pembrolizumab discontinuation. Data from ongoing clinical trials of pembrolizumab, in which therapy stopping rules were more formalized, may help address the question of the optimal treatment duration. Another key unmet question is the best way to assess the clinical benefit of pembrolizumab. Because immunotherapeutic agents may be associated with an initial increase in tumor burden followed by disease stabilization or response (22), revised response criteria that require confirmation of disease progression may better reflect the overall clinical benefit of these agents. The use of multiple criteria for assessing response in ongoing clinical trials of pembrolizumab may help answer this question.

Data from this first-in-human study provide insights into the safety, activity, and durability of response of pembrolizumab and provided the basis for enrolling patients in multiple melanoma and NSCLC expansion cohorts of KEYNOTE-001 (15, 18). Based on data from the randomized cohort of patients with ipilimumab-refractory melanoma (18), pembrolizumab was approved in the United States for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAFV600E mutation positive, a BRAF inhibitor. Further development of pembrolizumab is being pursued in more than 30 tumor types, including melanoma, NSCLC, hematologic malignancies, triple-negative breast cancer, head and neck squamous cell carcinoma, gastric cancer, and urothelial cancer. Appropriate AE management strategies, including the use of immunosuppressants, are being studied and synthesized based on experience from larger expansion studies of pembrolizumab.

Disclosure of Potential Conflicts of Interest

S.P. Kang, C. Chen, J.A. Lindia, and O. Laterza have ownership interest [including patents] in Merck. D. Rasco is a consultant/advisory board member for Celgene. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Patnaik, D. Rasco, K.P. Papadopoulos, J. Elassaiss-Schaap, R. Drengler, L. Smith, G. Espino, A. Daud, J.A. Lindia, R.H. Pierce, J.H. Yearley, D. Wu, O. Laterza, A.W. Tolcher


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Elassaiss-Schaap, L. Smith, G. Espino, K. Gergich, J.A. Lindia

For the Study Team


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Patnaik, D. Rasco, K.P. Papadopoulos, J. Elassaiss-Schaap, R. Drengler, L. Smith, G. Espino, A. Daud, J.A. Lindia, R.H. Pierce, J.H. Yearley, D. Wu, O. Laterza, A.W. Tolcher

Acknowledgments: The authors thank all clinical and research staff at the participating institutions for their support and contributions to this study.

Author Disclosure: All authors indicated no relevant financial relationships which could create a conflict of interest. This information was first published in Clinical Cancer Research; 21(19);10, 2015; DOI: 10.1158/1078-0432.CCR-14-2607.

Acknowledgments
Medical writing assistance was provided by Melanie Leby, PhD, and Cathy R. Winter, PhD, of The APO Group (Yardley, Pennsylvania). Noncompartmen-
tal analysis was performed by Maritelle van Zutphen of Merck. Population pharmacokinetics-pharmacodynamics modeling was performed by Stefan Roszeni, PhD, and Andreas Lindauer, PhD, of Merck. Jeff Sachs, PhD, of Merck led the design of the Part A-2 dose-escalation portion of the study. Andreas Lindauer, PhD, and Reaven Anderson, PhD, of Merck also contributed to the A-2 design. Additional data analysis was performed by Maxine Giamotti and Peggy Wong of Merck. Assistance with optimizing patient scans for inclusion in the manuscript was provided by Linda Gammage of Merck. Critical review of the manuscript was provided by Aline Reicin and Eric Rubin of Merck.

References
3. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfAMILY, upon pro-
4. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-
10. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immuno-
programmed death-receptor-1 treatment with pembrolizumab in ipilimu-
Clinical Cancer Research

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-2607

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2015/05/15/1078-0432.CCR-14-2607.DC1

Cited articles
This article cites 21 articles, 8 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/19/4286.full.html#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/21/19/4286.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.